The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome

J Clin Pharmacol. 2014 Oct;54(10):1079-92. doi: 10.1002/jcph.362. Epub 2014 Jul 18.


PCOS is one of the most common endocrine disorders affecting women and it is characterized by a combination of hyper-androgenism, chronic anovulation, and insulin resistance. While a significant progress has recently been made in the diagnosis for PCOS, the optimal infertility treatment remains to be determined. Two inositol isomers, myo-inositol (MI) and D-chiro-inositol (DCI) have been proven to be effective in PCOS treatment, by improving insulin resistance, serum androgen levels and many features of the metabolic syndrome. However, DCI alone, mostly when it is administered at high dosage, negatively affects oocyte quality, whereas the association MI/DCI, in a combination reproducing the plasma physiological ratio (40:1), represents a promising alternative in achieving better clinical results, by counteracting PCOS at both systemic and ovary level.

Keywords: embryo; infertility; inositol; oocyte; polycystic ovarian syndrome.

Publication types

  • Review

MeSH terms

  • Androgens / blood
  • Animals
  • Drug Therapy, Combination
  • Female
  • Humans
  • Inositol / administration & dosage
  • Inositol / chemistry
  • Inositol / therapeutic use*
  • Insulin Resistance
  • Oocytes / metabolism
  • Polycystic Ovary Syndrome / drug therapy*
  • Polycystic Ovary Syndrome / physiopathology
  • Stereoisomerism
  • Vitamin B Complex / administration & dosage
  • Vitamin B Complex / chemistry
  • Vitamin B Complex / therapeutic use*


  • Androgens
  • Vitamin B Complex
  • Inositol